StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN – Free Report) in a report issued on Monday. The brokerage issued a sell rating on the biotechnology company’s stock.
Evogene Trading Up 5.3 %
Shares of NASDAQ EVGN opened at $1.60 on Monday. The business has a fifty day simple moving average of $1.61 and a 200 day simple moving average of $3.00. The firm has a market capitalization of $8.58 million, a price-to-earnings ratio of -0.36 and a beta of 1.30. Evogene has a one year low of $1.20 and a one year high of $10.40.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC bought a new position in shares of Evogene Ltd. (NASDAQ:EVGN – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors own 10.40% of the company’s stock.
Evogene Company Profile
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Further Reading
- Five stocks we like better than Evogene
- Investing in the High PE Growth Stocks
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- How Do Stock Buybacks Affect Shareholders?
- Why Are These Companies Considered Blue Chips?
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
